Loading clinical trials...
Loading clinical trials...
A Randomized, Open-Label, Active-Controlled, Multi-Center, Phase III Clinical Study of Anti-PD-1 Antibody SHR-1210 vs. Investigator's Choice of Chemotherapy in Subjects With Locally Advanced or Metastatic Esophageal Cancer
Conditions
Interventions
camrelizumab
Docetaxel
+1 more
Locations
2
China
307 Hospital of PLA
Beijing, Beijing Municipality, China
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Start Date
May 5, 2017
Primary Completion Date
May 6, 2019
Completion Date
May 6, 2019
Last Updated
January 22, 2024
NCT06349642
NCT06549413
NCT00991094
NCT03948100
NCT06067438
NCT05059444
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions